Global Value-added Medicines (VAM) Market Growth (Status and Outlook) 2026-2032
The global Value-added Medicines (VAM) market size is predicted to grow from US$ 824 million in 2025 to US$ 1760 million in 2032; it is expected to grow at a CAGR of 11.7% from 2026 to 2032.
Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
United States market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Value-added Medicines (VAM) players cover Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?Value-added Medicines (VAM) Industry Forecast? looks at past sales and reviews total world Value-added Medicines (VAM) sales in 2025, providing a comprehensive analysis by region and market sector of projected Value-added Medicines (VAM) sales for 2026 through 2032. With Value-added Medicines (VAM) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Value-added Medicines (VAM) industry.
This Insight Report provides a comprehensive analysis of the global Value-added Medicines (VAM) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Value-added Medicines (VAM) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Value-added Medicines (VAM) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Value-added Medicines (VAM) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Value-added Medicines (VAM).
This report presents a comprehensive overview, market shares, and growth opportunities of Value-added Medicines (VAM) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
United States market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Value-added Medicines (VAM) players cover Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?Value-added Medicines (VAM) Industry Forecast? looks at past sales and reviews total world Value-added Medicines (VAM) sales in 2025, providing a comprehensive analysis by region and market sector of projected Value-added Medicines (VAM) sales for 2026 through 2032. With Value-added Medicines (VAM) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Value-added Medicines (VAM) industry.
This Insight Report provides a comprehensive analysis of the global Value-added Medicines (VAM) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Value-added Medicines (VAM) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Value-added Medicines (VAM) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Value-added Medicines (VAM) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Value-added Medicines (VAM).
This report presents a comprehensive overview, market shares, and growth opportunities of Value-added Medicines (VAM) market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Chronic Disease Treatment Drugs
- Infectious Disease Treatment Drugs
- Tumor Treatment Drugs
- Other
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Zentiva Group
- MS Pharma
- Towa International
- CNX Therapeutics
- ROVI
- Elpen
- Sandoz AG
- Colonis
- Adamed
- Hyloris Pharmaceuticals SA
- TIEFENBACHER GROUP
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Value-added Medicines (VAM) Market Size (2021-2032)
2.1.2 Value-added Medicines (VAM) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Value-added Medicines (VAM) by Country/Region (2021, 2025 & 2032)
2.2 Value-added Medicines (VAM) Segment by Type
2.2.1 Chronic Disease Treatment Drugs
2.2.2 Infectious Disease Treatment Drugs
2.2.3 Tumor Treatment Drugs
2.2.4 Other
2.2.5 Value-added Medicines (VAM) Market Size by Type
2.2.5.1 Value-added Medicines (VAM) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
2.3 Value-added Medicines (VAM) Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Other
2.3.4 Value-added Medicines (VAM) Market Size by Application
2.3.4.1 Value-added Medicines (VAM) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
3 VALUE-ADDED MEDICINES (VAM) MARKET SIZE BY PLAYER
3.1 Value-added Medicines (VAM) Market Size Market Share by Player
3.1.1 Global Value-added Medicines (VAM) Revenue by Player (2021-2026)
3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Player (2021-2026)
3.2 Global Value-added Medicines (VAM) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 VALUE-ADDED MEDICINES (VAM) BY REGION
4.1 Value-added Medicines (VAM) Market Size by Region (2021-2026)
4.2 Global Value-added Medicines (VAM) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Value-added Medicines (VAM) Market Size Growth (2021-2026)
4.4 APAC Value-added Medicines (VAM) Market Size Growth (2021-2026)
4.5 Europe Value-added Medicines (VAM) Market Size Growth (2021-2026)
4.6 Middle East & Africa Value-added Medicines (VAM) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Value-added Medicines (VAM) Market Size by Country (2021-2026)
5.2 Americas Value-added Medicines (VAM) Market Size by Type (2021-2026)
5.3 Americas Value-added Medicines (VAM) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Value-added Medicines (VAM) Market Size by Region (2021-2026)
6.2 APAC Value-added Medicines (VAM) Market Size by Type (2021-2026)
6.3 APAC Value-added Medicines (VAM) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Value-added Medicines (VAM) Market Size by Country (2021-2026)
7.2 Europe Value-added Medicines (VAM) Market Size by Type (2021-2026)
7.3 Europe Value-added Medicines (VAM) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Value-added Medicines (VAM) by Region (2021-2026)
8.2 Middle East & Africa Value-added Medicines (VAM) Market Size by Type (2021-2026)
8.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL VALUE-ADDED MEDICINES (VAM) MARKET FORECAST
10.1 Global Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.1.1 Global Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.1.2 Americas Value-added Medicines (VAM) Forecast
10.1.3 APAC Value-added Medicines (VAM) Forecast
10.1.4 Europe Value-added Medicines (VAM) Forecast
10.1.5 Middle East & Africa Value-added Medicines (VAM) Forecast
10.2 Americas Value-added Medicines (VAM) Forecast by Country (2027-2032)
10.2.1 United States Market Value-added Medicines (VAM) Forecast
10.2.2 Canada Market Value-added Medicines (VAM) Forecast
10.2.3 Mexico Market Value-added Medicines (VAM) Forecast
10.2.4 Brazil Market Value-added Medicines (VAM) Forecast
10.3 APAC Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.3.1 China Value-added Medicines (VAM) Market Forecast
10.3.2 Japan Market Value-added Medicines (VAM) Forecast
10.3.3 Korea Market Value-added Medicines (VAM) Forecast
10.3.4 Southeast Asia Market Value-added Medicines (VAM) Forecast
10.3.5 India Market Value-added Medicines (VAM) Forecast
10.3.6 Australia Market Value-added Medicines (VAM) Forecast
10.4 Europe Value-added Medicines (VAM) Forecast by Country (2027-2032)
10.4.1 Germany Market Value-added Medicines (VAM) Forecast
10.4.2 France Market Value-added Medicines (VAM) Forecast
10.4.3 UK Market Value-added Medicines (VAM) Forecast
10.4.4 Italy Market Value-added Medicines (VAM) Forecast
10.4.5 Russia Market Value-added Medicines (VAM) Forecast
10.5 Middle East & Africa Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.5.1 Egypt Market Value-added Medicines (VAM) Forecast
10.5.2 South Africa Market Value-added Medicines (VAM) Forecast
10.5.3 Israel Market Value-added Medicines (VAM) Forecast
10.5.4 Turkey Market Value-added Medicines (VAM) Forecast
10.6 Global Value-added Medicines (VAM) Forecast by Type (2027-2032)
10.7 Global Value-added Medicines (VAM) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Value-added Medicines (VAM) Forecast
11 KEY PLAYERS ANALYSIS
11.1 Zentiva Group
11.1.1 Zentiva Group Company Information
11.1.2 Zentiva Group Value-added Medicines (VAM) Product Offered
11.1.3 Zentiva Group Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Zentiva Group Main Business Overview
11.1.5 Zentiva Group Latest Developments
11.2 MS Pharma
11.2.1 MS Pharma Company Information
11.2.2 MS Pharma Value-added Medicines (VAM) Product Offered
11.2.3 MS Pharma Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 MS Pharma Main Business Overview
11.2.5 MS Pharma Latest Developments
11.3 Towa International
11.3.1 Towa International Company Information
11.3.2 Towa International Value-added Medicines (VAM) Product Offered
11.3.3 Towa International Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Towa International Main Business Overview
11.3.5 Towa International Latest Developments
11.4 CNX Therapeutics
11.4.1 CNX Therapeutics Company Information
11.4.2 CNX Therapeutics Value-added Medicines (VAM) Product Offered
11.4.3 CNX Therapeutics Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CNX Therapeutics Main Business Overview
11.4.5 CNX Therapeutics Latest Developments
11.5 ROVI
11.5.1 ROVI Company Information
11.5.2 ROVI Value-added Medicines (VAM) Product Offered
11.5.3 ROVI Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 ROVI Main Business Overview
11.5.5 ROVI Latest Developments
11.6 Elpen
11.6.1 Elpen Company Information
11.6.2 Elpen Value-added Medicines (VAM) Product Offered
11.6.3 Elpen Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Elpen Main Business Overview
11.6.5 Elpen Latest Developments
11.7 Sandoz AG
11.7.1 Sandoz AG Company Information
11.7.2 Sandoz AG Value-added Medicines (VAM) Product Offered
11.7.3 Sandoz AG Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Sandoz AG Main Business Overview
11.7.5 Sandoz AG Latest Developments
11.8 Colonis
11.8.1 Colonis Company Information
11.8.2 Colonis Value-added Medicines (VAM) Product Offered
11.8.3 Colonis Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Colonis Main Business Overview
11.8.5 Colonis Latest Developments
11.9 Adamed
11.9.1 Adamed Company Information
11.9.2 Adamed Value-added Medicines (VAM) Product Offered
11.9.3 Adamed Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Adamed Main Business Overview
11.9.5 Adamed Latest Developments
11.10 Hyloris Pharmaceuticals SA
11.10.1 Hyloris Pharmaceuticals SA Company Information
11.10.2 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product Offered
11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Hyloris Pharmaceuticals SA Main Business Overview
11.10.5 Hyloris Pharmaceuticals SA Latest Developments
11.11 TIEFENBACHER GROUP
11.11.1 TIEFENBACHER GROUP Company Information
11.11.2 TIEFENBACHER GROUP Value-added Medicines (VAM) Product Offered
11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 TIEFENBACHER GROUP Main Business Overview
11.11.5 TIEFENBACHER GROUP Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Value-added Medicines (VAM) Market Size (2021-2032)
2.1.2 Value-added Medicines (VAM) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Value-added Medicines (VAM) by Country/Region (2021, 2025 & 2032)
2.2 Value-added Medicines (VAM) Segment by Type
2.2.1 Chronic Disease Treatment Drugs
2.2.2 Infectious Disease Treatment Drugs
2.2.3 Tumor Treatment Drugs
2.2.4 Other
2.2.5 Value-added Medicines (VAM) Market Size by Type
2.2.5.1 Value-added Medicines (VAM) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
2.3 Value-added Medicines (VAM) Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Other
2.3.4 Value-added Medicines (VAM) Market Size by Application
2.3.4.1 Value-added Medicines (VAM) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
3 VALUE-ADDED MEDICINES (VAM) MARKET SIZE BY PLAYER
3.1 Value-added Medicines (VAM) Market Size Market Share by Player
3.1.1 Global Value-added Medicines (VAM) Revenue by Player (2021-2026)
3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Player (2021-2026)
3.2 Global Value-added Medicines (VAM) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 VALUE-ADDED MEDICINES (VAM) BY REGION
4.1 Value-added Medicines (VAM) Market Size by Region (2021-2026)
4.2 Global Value-added Medicines (VAM) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Value-added Medicines (VAM) Market Size Growth (2021-2026)
4.4 APAC Value-added Medicines (VAM) Market Size Growth (2021-2026)
4.5 Europe Value-added Medicines (VAM) Market Size Growth (2021-2026)
4.6 Middle East & Africa Value-added Medicines (VAM) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Value-added Medicines (VAM) Market Size by Country (2021-2026)
5.2 Americas Value-added Medicines (VAM) Market Size by Type (2021-2026)
5.3 Americas Value-added Medicines (VAM) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Value-added Medicines (VAM) Market Size by Region (2021-2026)
6.2 APAC Value-added Medicines (VAM) Market Size by Type (2021-2026)
6.3 APAC Value-added Medicines (VAM) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Value-added Medicines (VAM) Market Size by Country (2021-2026)
7.2 Europe Value-added Medicines (VAM) Market Size by Type (2021-2026)
7.3 Europe Value-added Medicines (VAM) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Value-added Medicines (VAM) by Region (2021-2026)
8.2 Middle East & Africa Value-added Medicines (VAM) Market Size by Type (2021-2026)
8.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL VALUE-ADDED MEDICINES (VAM) MARKET FORECAST
10.1 Global Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.1.1 Global Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.1.2 Americas Value-added Medicines (VAM) Forecast
10.1.3 APAC Value-added Medicines (VAM) Forecast
10.1.4 Europe Value-added Medicines (VAM) Forecast
10.1.5 Middle East & Africa Value-added Medicines (VAM) Forecast
10.2 Americas Value-added Medicines (VAM) Forecast by Country (2027-2032)
10.2.1 United States Market Value-added Medicines (VAM) Forecast
10.2.2 Canada Market Value-added Medicines (VAM) Forecast
10.2.3 Mexico Market Value-added Medicines (VAM) Forecast
10.2.4 Brazil Market Value-added Medicines (VAM) Forecast
10.3 APAC Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.3.1 China Value-added Medicines (VAM) Market Forecast
10.3.2 Japan Market Value-added Medicines (VAM) Forecast
10.3.3 Korea Market Value-added Medicines (VAM) Forecast
10.3.4 Southeast Asia Market Value-added Medicines (VAM) Forecast
10.3.5 India Market Value-added Medicines (VAM) Forecast
10.3.6 Australia Market Value-added Medicines (VAM) Forecast
10.4 Europe Value-added Medicines (VAM) Forecast by Country (2027-2032)
10.4.1 Germany Market Value-added Medicines (VAM) Forecast
10.4.2 France Market Value-added Medicines (VAM) Forecast
10.4.3 UK Market Value-added Medicines (VAM) Forecast
10.4.4 Italy Market Value-added Medicines (VAM) Forecast
10.4.5 Russia Market Value-added Medicines (VAM) Forecast
10.5 Middle East & Africa Value-added Medicines (VAM) Forecast by Region (2027-2032)
10.5.1 Egypt Market Value-added Medicines (VAM) Forecast
10.5.2 South Africa Market Value-added Medicines (VAM) Forecast
10.5.3 Israel Market Value-added Medicines (VAM) Forecast
10.5.4 Turkey Market Value-added Medicines (VAM) Forecast
10.6 Global Value-added Medicines (VAM) Forecast by Type (2027-2032)
10.7 Global Value-added Medicines (VAM) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Value-added Medicines (VAM) Forecast
11 KEY PLAYERS ANALYSIS
11.1 Zentiva Group
11.1.1 Zentiva Group Company Information
11.1.2 Zentiva Group Value-added Medicines (VAM) Product Offered
11.1.3 Zentiva Group Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Zentiva Group Main Business Overview
11.1.5 Zentiva Group Latest Developments
11.2 MS Pharma
11.2.1 MS Pharma Company Information
11.2.2 MS Pharma Value-added Medicines (VAM) Product Offered
11.2.3 MS Pharma Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 MS Pharma Main Business Overview
11.2.5 MS Pharma Latest Developments
11.3 Towa International
11.3.1 Towa International Company Information
11.3.2 Towa International Value-added Medicines (VAM) Product Offered
11.3.3 Towa International Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Towa International Main Business Overview
11.3.5 Towa International Latest Developments
11.4 CNX Therapeutics
11.4.1 CNX Therapeutics Company Information
11.4.2 CNX Therapeutics Value-added Medicines (VAM) Product Offered
11.4.3 CNX Therapeutics Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CNX Therapeutics Main Business Overview
11.4.5 CNX Therapeutics Latest Developments
11.5 ROVI
11.5.1 ROVI Company Information
11.5.2 ROVI Value-added Medicines (VAM) Product Offered
11.5.3 ROVI Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 ROVI Main Business Overview
11.5.5 ROVI Latest Developments
11.6 Elpen
11.6.1 Elpen Company Information
11.6.2 Elpen Value-added Medicines (VAM) Product Offered
11.6.3 Elpen Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Elpen Main Business Overview
11.6.5 Elpen Latest Developments
11.7 Sandoz AG
11.7.1 Sandoz AG Company Information
11.7.2 Sandoz AG Value-added Medicines (VAM) Product Offered
11.7.3 Sandoz AG Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Sandoz AG Main Business Overview
11.7.5 Sandoz AG Latest Developments
11.8 Colonis
11.8.1 Colonis Company Information
11.8.2 Colonis Value-added Medicines (VAM) Product Offered
11.8.3 Colonis Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Colonis Main Business Overview
11.8.5 Colonis Latest Developments
11.9 Adamed
11.9.1 Adamed Company Information
11.9.2 Adamed Value-added Medicines (VAM) Product Offered
11.9.3 Adamed Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Adamed Main Business Overview
11.9.5 Adamed Latest Developments
11.10 Hyloris Pharmaceuticals SA
11.10.1 Hyloris Pharmaceuticals SA Company Information
11.10.2 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product Offered
11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Hyloris Pharmaceuticals SA Main Business Overview
11.10.5 Hyloris Pharmaceuticals SA Latest Developments
11.11 TIEFENBACHER GROUP
11.11.1 TIEFENBACHER GROUP Company Information
11.11.2 TIEFENBACHER GROUP Value-added Medicines (VAM) Product Offered
11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 TIEFENBACHER GROUP Main Business Overview
11.11.5 TIEFENBACHER GROUP Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Value-added Medicines (VAM) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Value-added Medicines (VAM) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Chronic Disease Treatment Drugs
Table 4. Major Players of Infectious Disease Treatment Drugs
Table 5. Major Players of Tumor Treatment Drugs
Table 6. Major Players of Other
Table 7. Value-added Medicines (VAM) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Table 10. Value-added Medicines (VAM) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Table 13. Global Value-added Medicines (VAM) Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Value-added Medicines (VAM) Revenue Market Share by Player (2021-2026)
Table 15. Value-added Medicines (VAM) Key Players Head office and Products Offered
Table 16. Value-added Medicines (VAM) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Value-added Medicines (VAM) Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Table 21. Global Value-added Medicines (VAM) Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Value-added Medicines (VAM) Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Value-added Medicines (VAM) Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Value-added Medicines (VAM) Market Size Market Share by Country (2021-2026)
Table 25. Americas Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Table 27. Americas Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Table 29. APAC Value-added Medicines (VAM) Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Table 31. APAC Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Value-added Medicines (VAM) Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Value-added Medicines (VAM) Market Size Market Share by Country (2021-2026)
Table 35. Europe Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Value-added Medicines (VAM) Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Value-added Medicines (VAM)
Table 41. Key Market Challenges & Risks of Value-added Medicines (VAM)
Table 42. Key Industry Trends of Value-added Medicines (VAM)
Table 43. Global Value-added Medicines (VAM) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Value-added Medicines (VAM) Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Value-added Medicines (VAM) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Value-added Medicines (VAM) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. Zentiva Group Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 48. Zentiva Group Value-added Medicines (VAM) Product Offered
Table 49. Zentiva Group Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. Zentiva Group Main Business
Table 51. Zentiva Group Latest Developments
Table 52. MS Pharma Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 53. MS Pharma Value-added Medicines (VAM) Product Offered
Table 54. MS Pharma Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. MS Pharma Main Business
Table 56. MS Pharma Latest Developments
Table 57. Towa International Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 58. Towa International Value-added Medicines (VAM) Product Offered
Table 59. Towa International Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Towa International Main Business
Table 61. Towa International Latest Developments
Table 62. CNX Therapeutics Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 63. CNX Therapeutics Value-added Medicines (VAM) Product Offered
Table 64. CNX Therapeutics Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. CNX Therapeutics Main Business
Table 66. CNX Therapeutics Latest Developments
Table 67. ROVI Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 68. ROVI Value-added Medicines (VAM) Product Offered
Table 69. ROVI Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. ROVI Main Business
Table 71. ROVI Latest Developments
Table 72. Elpen Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 73. Elpen Value-added Medicines (VAM) Product Offered
Table 74. Elpen Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Elpen Main Business
Table 76. Elpen Latest Developments
Table 77. Sandoz AG Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 78. Sandoz AG Value-added Medicines (VAM) Product Offered
Table 79. Sandoz AG Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Sandoz AG Main Business
Table 81. Sandoz AG Latest Developments
Table 82. Colonis Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 83. Colonis Value-added Medicines (VAM) Product Offered
Table 84. Colonis Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Colonis Main Business
Table 86. Colonis Latest Developments
Table 87. Adamed Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 88. Adamed Value-added Medicines (VAM) Product Offered
Table 89. Adamed Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Adamed Main Business
Table 91. Adamed Latest Developments
Table 92. Hyloris Pharmaceuticals SA Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 93. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product Offered
Table 94. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Hyloris Pharmaceuticals SA Main Business
Table 96. Hyloris Pharmaceuticals SA Latest Developments
Table 97. TIEFENBACHER GROUP Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 98. TIEFENBACHER GROUP Value-added Medicines (VAM) Product Offered
Table 99. TIEFENBACHER GROUP Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. TIEFENBACHER GROUP Main Business
Table 101. TIEFENBACHER GROUP Latest Developments
Table 1. Value-added Medicines (VAM) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Value-added Medicines (VAM) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Chronic Disease Treatment Drugs
Table 4. Major Players of Infectious Disease Treatment Drugs
Table 5. Major Players of Tumor Treatment Drugs
Table 6. Major Players of Other
Table 7. Value-added Medicines (VAM) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Table 10. Value-added Medicines (VAM) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Table 13. Global Value-added Medicines (VAM) Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Value-added Medicines (VAM) Revenue Market Share by Player (2021-2026)
Table 15. Value-added Medicines (VAM) Key Players Head office and Products Offered
Table 16. Value-added Medicines (VAM) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Value-added Medicines (VAM) Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Table 21. Global Value-added Medicines (VAM) Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Value-added Medicines (VAM) Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Value-added Medicines (VAM) Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Value-added Medicines (VAM) Market Size Market Share by Country (2021-2026)
Table 25. Americas Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Table 27. Americas Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Table 29. APAC Value-added Medicines (VAM) Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Table 31. APAC Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Value-added Medicines (VAM) Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Value-added Medicines (VAM) Market Size Market Share by Country (2021-2026)
Table 35. Europe Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Value-added Medicines (VAM) Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Value-added Medicines (VAM) Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Value-added Medicines (VAM) Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Value-added Medicines (VAM)
Table 41. Key Market Challenges & Risks of Value-added Medicines (VAM)
Table 42. Key Industry Trends of Value-added Medicines (VAM)
Table 43. Global Value-added Medicines (VAM) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Value-added Medicines (VAM) Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Value-added Medicines (VAM) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Value-added Medicines (VAM) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. Zentiva Group Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 48. Zentiva Group Value-added Medicines (VAM) Product Offered
Table 49. Zentiva Group Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. Zentiva Group Main Business
Table 51. Zentiva Group Latest Developments
Table 52. MS Pharma Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 53. MS Pharma Value-added Medicines (VAM) Product Offered
Table 54. MS Pharma Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. MS Pharma Main Business
Table 56. MS Pharma Latest Developments
Table 57. Towa International Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 58. Towa International Value-added Medicines (VAM) Product Offered
Table 59. Towa International Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Towa International Main Business
Table 61. Towa International Latest Developments
Table 62. CNX Therapeutics Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 63. CNX Therapeutics Value-added Medicines (VAM) Product Offered
Table 64. CNX Therapeutics Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. CNX Therapeutics Main Business
Table 66. CNX Therapeutics Latest Developments
Table 67. ROVI Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 68. ROVI Value-added Medicines (VAM) Product Offered
Table 69. ROVI Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. ROVI Main Business
Table 71. ROVI Latest Developments
Table 72. Elpen Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 73. Elpen Value-added Medicines (VAM) Product Offered
Table 74. Elpen Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Elpen Main Business
Table 76. Elpen Latest Developments
Table 77. Sandoz AG Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 78. Sandoz AG Value-added Medicines (VAM) Product Offered
Table 79. Sandoz AG Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Sandoz AG Main Business
Table 81. Sandoz AG Latest Developments
Table 82. Colonis Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 83. Colonis Value-added Medicines (VAM) Product Offered
Table 84. Colonis Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Colonis Main Business
Table 86. Colonis Latest Developments
Table 87. Adamed Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 88. Adamed Value-added Medicines (VAM) Product Offered
Table 89. Adamed Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Adamed Main Business
Table 91. Adamed Latest Developments
Table 92. Hyloris Pharmaceuticals SA Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 93. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product Offered
Table 94. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Hyloris Pharmaceuticals SA Main Business
Table 96. Hyloris Pharmaceuticals SA Latest Developments
Table 97. TIEFENBACHER GROUP Details, Company Type, Value-added Medicines (VAM) Area Served and Its Competitors
Table 98. TIEFENBACHER GROUP Value-added Medicines (VAM) Product Offered
Table 99. TIEFENBACHER GROUP Value-added Medicines (VAM) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. TIEFENBACHER GROUP Main Business
Table 101. TIEFENBACHER GROUP Latest Developments
LIST OF FIGURES
Figure 1. Value-added Medicines (VAM) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Value-added Medicines (VAM) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Value-added Medicines (VAM) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Value-added Medicines (VAM) Sales Market Share by Country/Region (2025)
Figure 8. Value-added Medicines (VAM) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Value-added Medicines (VAM) Market Size Market Share by Type in 2025
Figure 10. Value-added Medicines (VAM) in Hospital
Figure 11. Global Value-added Medicines (VAM) Market: Hospital (2021-2026) & ($ millions)
Figure 12. Value-added Medicines (VAM) in Clinic
Figure 13. Global Value-added Medicines (VAM) Market: Clinic (2021-2026) & ($ millions)
Figure 14. Value-added Medicines (VAM) in Other
Figure 15. Global Value-added Medicines (VAM) Market: Other (2021-2026) & ($ millions)
Figure 16. Global Value-added Medicines (VAM) Market Size Market Share by Application in 2025
Figure 17. Global Value-added Medicines (VAM) Revenue Market Share by Player in 2025
Figure 18. Global Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 20. APAC Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 21. Europe Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 23. Americas Value-added Medicines (VAM) Value Market Share by Country in 2025
Figure 24. United States Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Value-added Medicines (VAM) Market Size Market Share by Region in 2025
Figure 29. APAC Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Figure 31. China Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Value-added Medicines (VAM) Market Size Market Share by Country in 2025
Figure 38. Europe Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 54. APAC Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 55. Europe Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 57. United States Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 58. Canada Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 61. China Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 62. Japan Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 63. Korea Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 65. India Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 66. Australia Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 67. Germany Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 68. France Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 69. UK Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 70. Italy Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 71. Russia Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 74. Israel Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 76. Global Value-added Medicines (VAM) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Value-added Medicines (VAM) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 1. Value-added Medicines (VAM) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Value-added Medicines (VAM) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Value-added Medicines (VAM) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Value-added Medicines (VAM) Sales Market Share by Country/Region (2025)
Figure 8. Value-added Medicines (VAM) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Value-added Medicines (VAM) Market Size Market Share by Type in 2025
Figure 10. Value-added Medicines (VAM) in Hospital
Figure 11. Global Value-added Medicines (VAM) Market: Hospital (2021-2026) & ($ millions)
Figure 12. Value-added Medicines (VAM) in Clinic
Figure 13. Global Value-added Medicines (VAM) Market: Clinic (2021-2026) & ($ millions)
Figure 14. Value-added Medicines (VAM) in Other
Figure 15. Global Value-added Medicines (VAM) Market: Other (2021-2026) & ($ millions)
Figure 16. Global Value-added Medicines (VAM) Market Size Market Share by Application in 2025
Figure 17. Global Value-added Medicines (VAM) Revenue Market Share by Player in 2025
Figure 18. Global Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 20. APAC Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 21. Europe Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Value-added Medicines (VAM) Market Size 2021-2026 ($ millions)
Figure 23. Americas Value-added Medicines (VAM) Value Market Share by Country in 2025
Figure 24. United States Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Value-added Medicines (VAM) Market Size Market Share by Region in 2025
Figure 29. APAC Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Figure 31. China Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Value-added Medicines (VAM) Market Size Market Share by Country in 2025
Figure 38. Europe Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Value-added Medicines (VAM) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Value-added Medicines (VAM) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Value-added Medicines (VAM) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 54. APAC Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 55. Europe Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 57. United States Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 58. Canada Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 61. China Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 62. Japan Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 63. Korea Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 65. India Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 66. Australia Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 67. Germany Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 68. France Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 69. UK Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 70. Italy Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 71. Russia Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 74. Israel Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
Figure 76. Global Value-added Medicines (VAM) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Value-added Medicines (VAM) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Value-added Medicines (VAM) Market Size 2027-2032 ($ millions)
